AstraZeneca PLC/Merck & Co. Inc.'s Lynparza is breaking new ground in ovarian cancer with the first approval of a PARP inhibitor as first-line maintenance therapy in BRCA-mutated ovarian cancer.
After a speedy review, the US FDA approved Lynparza (olaparib) Dec. 19 as a monotherapy in BRCA+ patients in partial or complete response to first-line platinum-based chemotherapy. The companies had announced acceptance of the filing on Nov. 12, with expectations of approval in the first quarter of 2019; the application had priority review
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?